SciGen is a high growth biopharmaceutical company that develops, manufactures and markets biotechnology derived products. SciGen's focus is in the areas of endocrinology, oncology and immunology. Its product portfolio includes vaccines and therapeutics. The company’s portfolio consists of biosimilar products such as human growth hormone, recombinant human insulin, GCSF, EPO, interferon alfa, and a third generation hepatitis B vaccine. All of SciGen’s products have undergone substantial clinical development and trials, and are in the process of securing health registration.

SciGen’s strategy is to focus on biosimilars (follow-on proteins) in order to minimize the risk of early stage product development. SciGen has created its own research and development centre based in Israel in order to focus on E.coli bacteria and mammalian cell (CHO cell) technology. At SciGen’s R&D center continued advancement of its current molecules and other R&D activities are ongoing. SciGen also collaborates with strategic partners and institutions in order to continuously add & improve its pipeline.